IOVA Iovance Corp: Market Valuation

Iovance Biotherapeutics (IOVA) is expanding its clinical presence following the approval of its melanoma drug to meet massive patient demand. However, international patent protection and trade barriers create risks for overseas registration. The price trend captured at 3.59 complements data regarding the complexity of cryogenic transport for biomaterials, where delivery speed is critical for patient survival.

Iovance Biotherapeutics, Inc. - IOVA Market Capitalization (period 07/04/2022 - 11/14/2026)

Iovance Corp - analytical breakdowns and key metrics (IOVA)

- market price and analyst price targets:

Price Chart Iovance Biotherapeutics, Inc.|IOVA - Average Forecast Price

- company stock capitalization data:

Market Valuation Iovance Corp|IOVA - Total Company Value

- business book valuation details:

Book Value per Share Iovance Biotherapeutics|IOVA - Book Capitalization|Market Value to Book Value Ratio iovance.com|IOVA - Company Assets

- business debt structure and liquidity details:

- financial results and valuation multiples details:

IOVA - Company Net Income|Projected Future Earnings Iovance Biotherapeutics|IOVA - Market Cap to Net Income Ratio|Projected Price to Earnings Iovance|IOVA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Iovance Corp|IOVA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Iovance Biotherapeutics|IOVA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months iovance.com|IOVA - Net earnings per share growth this year|Net earnings per share growth forecast for next year Iovance Biotherapeutics

- total revenue and sales volume data:

IOVA - Company Sales|Company Future Sales Volume Iovance Biotherapeutics, Inc.|IOVA - P/S Multiple|Price-to-Projected Revenue Ratio Iovance Corp

Analysis of all company metrics:IOVA (Iovance Biotherapeutics, Inc.)

Professional managers utilize fundamental metrics to filter assets, assessing market value as the aggregate result of quotes and available liquidity. The dynamics of the total market valuation reflect the capital inflow into Iovance Biotherapeutics (IOVA), driven by the expansion of the clinical pipeline and the diversification of therapies against various solid tumors, which directly impacts the issuer's investment attractiveness.

Competitor analysis